Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 27, 2009 Brian Orelli	Pfizer's and Merck's Loss Is These Companies' Gain Are Pfizer and Merck too busy integrating now to take advantage of additional acquisitions?
The Motley Fool December 22, 2009 Brian Orelli	Some Incyte Into Why These Drugs Rock Eli Lilly jumps on the oral-drug-for-rheumatoid-arthritis bandwagon.
Bio-IT World September 2006 John Russell	Informatics Cornucopia Predictive Informatics, the hopeful title of a session at last month's Drug Discovery Technology & Development World Congress, remains an enticing but mostly elusive goal. Asked what systems biology would look in five years and what will constitute success, panelists offered the following.
The Motley Fool March 24, 2009 Robert Steyer	Drugmakers Diversify -- Again Merck and Pfizer choose businesses they once eschewed.
Bio-IT World November 2006 Wendy Wolfson	Oracle OpenWorld 2006: Pharma Stuck on Semantic Web At the recent Oracle OpenWorld conference, pharma executives offered evidence that some, at least, are using the semantic web to work smarter and lower drug development costs.
The Motley Fool October 23, 2009 Brian Orelli	Swine Flu Doesn't Need to Save Novartis The company is looking healthy all on its own.
Bio-IT World August 2005 Johan Bostrom	Agilent Acquisitions Bolster Portfolio of Products A string of acquisitions is helping Agilent Technologies establish itself as a major player in informatics for analytical laboratories, and its expanding product portfolio has made it a serious player in laboratory analysis automation and software integration.
Bio-IT World June 2006	3rd Millennium Goes Out on a LIMS Commercial laboratory information systems have a bad reputation. Conventional wisdom is they are expensive and too rigid. Now, a small previously consulting-only company is changing that with their award-winning offering for microarray research.
The Motley Fool October 30, 2009 Brian Orelli	World's Scariest Stocks: Pfizer For Pfizer, the big, scary unknown comes from whether it can integrate its recent acquisition of Wyeth.
The Motley Fool July 28, 2011 Melly Alazraki	J&J or Novartis? Novartis' businesses are an investor's delight; J&J's improving but isn't there yet.
The Motley Fool February 29, 2008 Brian Orelli	2007 Pharma Roundup How did big pharma do in 2007? With the drug sector earnings season winding down, now seems like a good time to take a look at how they fared and, more importantly, where they're headed.
Bio-IT World November 2006 Kevin Davies	Building a Bridge Over Pharma with IT More than 100 enthusiastic delegates bridging the full breadth of the drug development pipeline gathered recently for the second annual Bridging Pharma and IT conference. Here are some highlights.
The Motley Fool October 30, 2010 Anand Chokkavelu	7 Pharma Stocks Near 52-Week Highs Here are the top seven companies in the pharmaceutical space (by market cap) that are within spitting distance of their 52-week highs: J&J... Novartis... Merck... GlaxoSmithKline... Abbott... AstraZeneca... Novo Nordisk...
The Motley Fool December 21, 2006 Ryan Fuhrmann	Dueling Fools: Merck Bear Investors, because of its recent run-up, the risk/reward tradeoff is not very compelling. There are safer, more lucrative ways to invest in the space.
CIO October 15, 2001 Stephanie Overby	Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age...
The Motley Fool August 12, 2010 Brian Orelli	Pfizer: Strengths, Weaknesses, Opportunities, Threats Knowing them all makes it easier to judge an investment.
The Motley Fool November 5, 2009 Brian Orelli	Slow Down There, Merck Merck CEO Richard Clark says his company is looking to do more deals than ever, perhaps "even try to double" the current rate of 50 per year.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Looking at other big pharma peers, Merck is dead last when it comes to expected three- to five-year EPS growth. Why buy a troubled pharma when better options exist?
The Motley Fool July 7, 2010 Dave Mock	A Big Upgrade for Novartis This bullish call comes from more than just one analyst.
The Motley Fool August 12, 2011 David Williamson	What Happened to U.S. Pharma? How did the domestic pharmaceutical industry fare in the most recent quarter?
The Motley Fool May 12, 2009 Brian Orelli	Another Reason to Hate Big Pharma's M&A As we get closer to Pfizer and Merck wrapping up their deals, it looks like a new group is voicing their displeasure: external partners.
The Motley Fool June 30, 2006 Stephen D. Simpson	Johnson & Johnson: This Is More Like It Filling out the drug and device businesses will be good for growth. Investors, take note.
Bio-IT World April 2006 John Russell	Pfizer's Pursuit of Technology Can this $50-billion-plus, 115,000-employee behemoth succeed where other pharma giants have failed and successfully institutionalize the effort to find and develop critical new technology? Should it even try?
The Motley Fool July 21, 2006 Stephen D. Simpson	Lilly Wilts Neither the valuation nor the pipeline of this pharma makes for a compelling investment case.
Bio-IT World July 14, 2004 Davies & Russell	The Sweet Hereafter Novartis' stunning new research home in a former candy factory is but one ingredient in a bold new recipe for success that embraces leadership, culture, science, and technology.
The Motley Fool October 18, 2005 Stephen D. Simpson	More Good News From Novartis This Swiss drug giant continues to post steady growth. Investors, take note.
The Motley Fool March 18, 2009 Brian Orelli	Merck Pummels Pfizer One of these acquisitions is not like the other.
The Motley Fool June 15, 2010 Brian Orelli	Pfizer Focuses, Investors Should Cheer The culling of the pipeline continues at Pfizer. While that's bad news for partners that signed on with the company or with Wyeth before the merger it's a good move for Pfizer.
The Motley Fool March 14, 2011 Brian Orelli	This Deal Is No Dog Eli Lilly picks up Johnson & Johnson's European animal-health business.
Bio-IT World Dec 2006/Jan 2007 Allison Proffitt	'An Unfortunate Storm': Tripos CEO Discusses Company Future Tripos announced that it has successfully sold its Discovery Informatics business to Vector Capital. Despite the company's difficulties, including a collapsed share price, president and CEO John McAllister is upbeat about the company's future.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Rebuttal There's a reason why Merck's stock is cheap: weak pipeline, weak prospects.
Bio-IT World May 2006 Kevin Davies	Trailblazers Test Public Markets Three companies in postgenomic fields are going public. Infinity Pharmaceuticals, Perlegen Sciences, and Entelos announced they would be entering the public markets by means of merger, IPO, and institutional offering.
The Motley Fool December 18, 2008 Brian Orelli	Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009.
The Motley Fool April 27, 2009 Jim Mueller	Foolish Forecast: Pfizer's Out of the Starting Gate In advance of earnings, analyst's expect revenue down 6%, but none are saying to dump the stock.
The Motley Fool April 17, 2007 Ryan Fuhrmann	Clean Bill of Health at Eli Lilly Lilly recorded another solid quarter, but its valuation is a little rich.
The Motley Fool August 23, 2004 Ben McClure	Rethinking Big Pharma Risk is knocking Big Pharma stocks down. They won't be getting up anytime soon. Competition, soaring R&D costs, shifting business models, and political meddling combine to make drug stocks a riskier place to invest.
Bio-IT World November 2005	Bridges and Boundaries in Drug Discovery Research Good communication, blurring cultural boundaries, and strong project governance may be as, if not more, important as sweeping technology solutions when it comes to converging discovery and IT and expediting drug development.
Bio-IT World February 2006 Kevin Davies	Curtain Opens on Life Sciences Expo Highlights of the upcoming Life Sciences Conference + Expo: Keynotes... Conference Tracks... Speakers... Educational workshops... etc.
The Motley Fool January 28, 2010 Brian Orelli	Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds.
The Motley Fool December 14, 2007 Brian Orelli	Panel Kills Merck's Hope of OTC Status An FDA advisory panel isn't convinced that Merck's cholesterol-lowering drug MEVACOR deserves OTC status.
The Motley Fool October 21, 2004 Roger Nusbaum	Pictures of Lilly Eli Lilly's numbers get lost in the wake of Merck and Pfizer. While the market waits for drug stocks to recover, investors can collect Lilly's 2.5%, safe, dividend.
The Motley Fool December 24, 2007 Rick Aristotle Munarriz	4 Stocks That Took a Hike These stocks recently raised their dividends: Pfizer... Eli Lilly... Moody's... Waste Management...
The Motley Fool October 22, 2007 Brian Lawler	Modest Numbers From Eli Lilly Its sales were up for the quarter, but a new drug might be the best indicator of its prospects. Lilly's pipeline will dictate its near-term future.
The Motley Fool January 27, 2004 Jeff Hwang	Merck in the Balance These are troubled times for Merck. Restructuring charges, Zocor sales woes, and a new distribution program hamper earnings.
The Motley Fool October 19, 2009 Brian Orelli	Foolish Forecast: A Last Look at "Mini" Pfizer In advance of Pfizer's last earnings report before their acquisition of Wyeth, analysts expect a drop in sales and a bigger bottom line decrease.
The Motley Fool March 23, 2009 Brian Orelli	Which Pharmas Still Have Cash? Pharmaceutical mergers-and-acquisitions activity has been jumping for the past few months, but the consolidation can't go on forever.
Bio-IT World August 13, 2002 Russell & Dodge	Necessary Liaisons: Making Standards Work Caroline Kovac, IBM Corp.'s general manager for life sciences, talks about the need for standards and her take on the troubled informatics world.
The Motley Fool March 16, 2005 Cliff Malings	Nice of You to Notice Novartis The Street finally pays attention to a longtime pharma winner on news of a major generic-drug acquisition.
The Motley Fool February 22, 2005 Charly Travers	Is Big Pharma a Bargain? While much of the drug sector is looking pretty tasty, Pfizer, with its attractive relative valuation, dominant marketing presence, and willingness to buy up blockbuster drugs, heads the list.
The Motley Fool September 30, 2010 Brian Orelli	Chief Justice Roberts Sold Pfizer. Should You? Maybe, but not for the same reason.